These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 31269018

  • 1. Estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales: A modelling study.
    Choi YH, Andrews N, Miller E.
    PLoS Med; 2019 Jul; 16(7):e1002845. PubMed ID: 31269018
    [Abstract] [Full Text] [Related]

  • 2. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S, Menzies R, Chiu C, Toms C, Blyth CC, Krause V, McIntyre P.
    Clin Infect Dis; 2017 Jan 15; 64(2):175-183. PubMed ID: 27986682
    [Abstract] [Full Text] [Related]

  • 3. Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease.
    Melegaro A, Choi YH, George R, Edmunds WJ, Miller E, Gay NJ.
    BMC Infect Dis; 2010 Apr 08; 10():90. PubMed ID: 20377886
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
    Andrews N, Kent A, Amin-Chowdhury Z, Sheppard C, Fry N, Ramsay M, Ladhani SN.
    Vaccine; 2019 Jul 26; 37(32):4491-4498. PubMed ID: 31272872
    [Abstract] [Full Text] [Related]

  • 5. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF.
    Vaccine; 2013 Dec 16; 31(52):6232-8. PubMed ID: 24176490
    [Abstract] [Full Text] [Related]

  • 6. The herd effects of infant PCV7/PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation; a nationwide study in Israel.
    Regev-Yochay G, Katzir M, Strahilevitz J, Rahav G, Finn T, Miron D, Maor Y, Chazan B, Schindler Y, Dagan R, IAIPD group.
    Vaccine; 2017 Apr 25; 35(18):2449-2456. PubMed ID: 28342668
    [Abstract] [Full Text] [Related]

  • 7. Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England.
    Southern J, Andrews N, Sandu P, Sheppard CL, Waight PA, Fry NK, Van Hoek AJ, Miller E.
    PLoS One; 2018 Apr 25; 13(5):e0195799. PubMed ID: 29799839
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia.
    Gidding HF, McCallum L, Fathima P, Moore HC, Snelling TL, Blyth CC, Jayasinghe S, Giele C, de Klerk N, Andrews RM, McIntyre PB, ACIR linkage Investigator Team.
    Vaccine; 2018 May 03; 36(19):2650-2656. PubMed ID: 29627233
    [Abstract] [Full Text] [Related]

  • 9. Long-term effect of pneumococcal conjugate vaccines on invasive pneumococcal disease incidence among people of all ages from national, active, laboratory-based surveillance in South Africa, 2005-19: a cohort observational study.
    von Gottberg A, Kleynhans J, de Gouveia L, Tempia S, Meiring S, Quan V, du Plessis M, von Mollendorf C, Crowther-Gibson P, Avenant T, du Plessis N, Kularatne R, Chibabhai V, Madhi SA, Klugman KP, Whitney CG, Cohen C, GERMS-SA.
    Lancet Glob Health; 2024 Sep 03; 12(9):e1470-e1484. PubMed ID: 39151982
    [Abstract] [Full Text] [Related]

  • 10. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
    De Wals P, Lefebvre B, Deceuninck G, Longtin J.
    Vaccine; 2018 Jan 08; 36(3):421-426. PubMed ID: 29224962
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children.
    Jayasinghe S, Chiu C, Menzies R, Lehmann D, Cook H, Giele C, Krause V, McIntyre P.
    Vaccine; 2015 Nov 27; 33(48):6666-74. PubMed ID: 26519550
    [Abstract] [Full Text] [Related]

  • 13. Potential impact of replacing the 13-valent pneumococcal conjugate vaccine with 15-valent or 20-valent pneumococcal conjugate vaccine in the 1 + 1 infant schedule in England: a modelling study.
    Choi YH, Bertran M, Litt DJ, Ladhani SN, Miller E.
    Lancet Public Health; 2024 Sep 27; 9(9):e654-e663. PubMed ID: 39153492
    [Abstract] [Full Text] [Related]

  • 14. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study.
    Miller E, Andrews NJ, Waight PA, Slack MP, George RC.
    Lancet Infect Dis; 2011 Oct 27; 11(10):760-8. PubMed ID: 21621466
    [Abstract] [Full Text] [Related]

  • 15. Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England.
    Moore CE, Paul J, Foster D, Mahar SA, Griffiths D, Knox K, Peto TE, Walker AS, Crook DW, Oxford Invasive Pneumococcal Surveillance Group.
    J Infect Dis; 2014 Oct 01; 210(7):1001-11. PubMed ID: 24719477
    [Abstract] [Full Text] [Related]

  • 16. Towards the 13-valent pneumococcal conjugate universal vaccination: effectiveness in the transition era between PCV7 and PCV13 in Italy, 2010-2013.
    Martinelli D, Pedalino B, Cappelli MG, Caputi G, Sallustio A, Fortunato F, Tafuri S, Cozza V, Germinario C, Chironna M, Prato R, Apulian Group for the surveillance of pediatric IPD.
    Hum Vaccin Immunother; 2014 Oct 01; 10(1):33-9. PubMed ID: 24096297
    [Abstract] [Full Text] [Related]

  • 17. 7-Valent pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of serotype replacement?
    Choi YH, Jit M, Gay N, Andrews N, Waight PA, Melegaro A, George R, Miller E.
    PLoS One; 2011 Oct 01; 6(10):e26190. PubMed ID: 22022559
    [Abstract] [Full Text] [Related]

  • 18. Mathematical modelling long-term effects of replacing Prevnar7 with Prevnar13 on invasive pneumococcal diseases in England and Wales.
    Choi YH, Jit M, Flasche S, Gay N, Miller E.
    PLoS One; 2012 Oct 01; 7(7):e39927. PubMed ID: 22808073
    [Abstract] [Full Text] [Related]

  • 19. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L, Lévy-Bruhl D, Microbiologists of Epibac, ORP Networks.
    Vaccine; 2015 Jan 03; 33(2):359-66. PubMed ID: 25448105
    [Abstract] [Full Text] [Related]

  • 20. Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study.
    Bertran M, D'Aeth JC, Abdullahi F, Eletu S, Andrews NJ, Ramsay ME, Litt DJ, Ladhani SN.
    Lancet Infect Dis; 2024 May 03; 24(5):546-556. PubMed ID: 38310905
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.